FDA-cleared profile

Syngo.via RT Image Suite

Siemens Medical Solutions USA, Inc. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

syngo.via RT Image Suite VB50 supports trained radiation-oncology professionals with multimodality visualization, registration, contouring, simple treatment preparation, and DICOM export; this release expanded deep-learning automatic contouring.

Clinical role
Multimodality simulation, image review, contouring, and treatment-preparation workspace
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
Withdrawn

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyRadiotherapy Planning Imaging · Multi-region
  • Workflow roleMultimodality simulation, image review, contouring, and treatment-preparation workspace
  • Required inputAnatomical, functional, and multi-parametric images such as but not limited to CT, PET, PET/CT, MRI, and Linac Cone Beam CT (CBCT) images; DICOM RT structure sets may be loaded and stored.
  • Output and human actionContours, images and treatment plans can subsequently be exported to a Treatment Planning System; the software provides functionalities to create simple geometric treatment plans and generate a synthetic CT based on multiple pre-defined MR acquisitions.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
syngo.via RT Image Suite VB50 supports trained radiation-oncology professionals with multimodality visualization, registration, contouring, simple treatment preparation, and DICOM export; this release expanded deep-learning automatic contouring.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Multimodality simulation, image review, contouring, and treatment-preparation workspace
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Anatomical, functional, and multi-parametric images such as but not limited to CT, PET, PET/CT, MRI, and Linac Cone Beam CT (CBCT) images; DICOM RT structure sets may be loaded and stored.
  • Exact FDA submission
  • Checked 2026-09-19

The replacement uses only the packet's listed image modalities and DICOM RT structure-set function; 4D CT and RT Dose are not retained.

Output and clinician action
Contours, images and treatment plans can subsequently be exported to a Treatment Planning System; the software provides functionalities to create simple geometric treatment plans and generate a synthetic CT based on multiple pre-defined MR acquisitions.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication supports contours, images, treatment plans, simple geometric treatment plans, synthetic CT, and export to a Treatment Planning System; it does not support ventilation results.

Care setting
Radiation-therapy departments in hospitals, clinics, and other qualified treatment-planning facilities.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Medical professionals.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet supports the general phrase medical professional but does not identify the dossier's radiation-oncology role list.

Evidence summary
FDA summaries include release-specific software verification and clinical or nonclinical testing for automatic contouring, Synthetic CT, ventilation, and workflow changes. A vendor-collaborative VB40 clinical study reported substantial time savings but also requires exact-version, structure, and local-case-mix validation. Exact FDA recalls add important geometry, configuration, and structure-set completeness controls for VB40 and VB60.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA summaries include release-specific software verification and clinical or nonclinical testing for automatic contouring, Synthetic CT, ventilation, and workflow changes. A vendor-collaborative VB40 clinical study reported substantial time savings but also requires exact-version, structure, and local-case-mix validation. Exact FDA recalls add important geometry, configuration, and structure-set completeness controls for VB40 and VB60.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, and release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, and release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

Segmentation evaluation cohort

112 subjects

  • EndpointSubjects in the automatic-segmentation test set
  • PopulationSyngo.via RT Image Suite testing described in K201444
  • Tested versionsyngo.via RT Image Suite SOMARIS/8 VB50

Detection rate for newly added organs

100 %

  • EndpointDetection rate reported for newly added organs
  • PopulationSyngo.via RT Image Suite testing described in K201444
  • Tested versionsyngo.via RT Image Suite SOMARIS/8 VB50

VB40 breast time saving

87.6 %

  • EndpointReported automatic-contouring time reduction for breast cases
  • PopulationVB40 clinical validation
  • Tested versionsyngo.via RT Image Suite VB40

VB40 thorax time saving

93.5 %

  • EndpointReported automatic-contouring time reduction for thorax cases
  • PopulationVB40 clinical validation
  • Tested versionsyngo.via RT Image Suite VB40

VB40 pelvis time saving

82.2 %

  • EndpointReported automatic-contouring time reduction for male pelvis cases
  • PopulationVB40 clinical validation
  • Tested versionsyngo.via RT Image Suite VB40

K201444 FDA performance package for Syngo.via RT Image Suite

  • DesignManufacturer software verification plus release-specific automatic-contouring, Synthetic CT, ventilation, DICOM, or workflow validation
  • PopulationRelease-specific multimodality radiotherapy cases and functions described in the FDA summary
  • Scopeexact submission
  • Tested versionsyngo.via RT Image Suite SOMARIS/8 VB50
  • IndependenceSponsor or vendor study

K201444

Manufacturer evidence submitted for substantial equivalence. VB50 expanded automatic contouring structures and converted head-and-neck contouring from atlas-based to deep-learning methods; its segmentation evaluation used 112 subjects.

Clinical validation of Siemens syngo.via automatic contouring

  • DesignRetrospective clinical validation with three independent contour reviewers
  • Population95 patients with lung, breast, or male pelvic cancer and more than 600 organ-at-risk contours
  • Scopeproduct family
  • Tested versionsyngo.via RT Image Suite VB40
  • Samplen=95
  • Sites1
  • IndependenceSponsor or vendor study

PMID 36865668 · PMCID PMC9972393

Three authors were affiliated with Siemens Healthineers. Results for VB40 should not be transferred to another release without local validation.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K201444 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists. Maintain ongoing FDA and vendor surveillance.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS Radiation Oncology Model material. Evaluate the product within the radiation-therapy planning service line using net staff time after review, plan quality, rework, throughput, implementation cost, and recurring cost.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Anatomical, functional, and multi-parametric images such as but not limited to CT, PET, PET/CT, MRI, and Linac Cone Beam CT (CBCT) images; DICOM RT structure sets may be loaded and stored.

    Scope: Exact FDA submission. The replacement uses only the packet's listed image modalities and DICOM RT structure-set function; 4D CT and RT Dose are not retained.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K201444: Syngo.via RT Image Suite

  2. Routing

    Source context, not route validation: Client-server radiation-oncology software with DICOM image, RT Structure Set, and RT Dose exchange and export to treatment-planning systems; optional modules and scanner dependencies vary by release.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K201444: Syngo.via RT Image Suite · syngo.via RT Image Suite product page

  3. AI processing

    Source context, not route validation: A client-server syngo.via environment integrated with imaging and treatment-planning workflows. Determine server sizing, client locations, licenses, DICOM routes, scanner dependencies, support access, and disaster-recovery requirements for the installed release.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K201444: Syngo.via RT Image Suite · syngo.via RT Image Suite product page

  4. Returned objects

    Source context, not route validation: Contours, images and treatment plans can subsequently be exported to a Treatment Planning System; the software provides functionalities to create simple geometric treatment plans and generate a synthetic CT based on multiple pre-defined MR acquisitions.

    Scope: Exact FDA submission. The exact indication supports contours, images, treatment plans, simple geometric treatment plans, synthetic CT, and export to a Treatment Planning System; it does not support ventilation results.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K201444: Syngo.via RT Image Suite

  5. Viewer/worklist/report

    Unresolved route: Contours, images and treatment plans can subsequently be exported to a Treatment Planning System; the software provides functionalities to create simple geometric treatment plans and generate a synthetic CT based on multiple pre-defined MR acquisitions.

    Scope: Exact FDA submission. The exact indication supports contours, images, treatment plans, simple geometric treatment plans, synthetic CT, and export to a Treatment Planning System; it does not support ventilation results.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K201444: Syngo.via RT Image Suite

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
A client-server syngo.via environment integrated with imaging and treatment-planning workflows. Determine server sizing, client locations, licenses, DICOM routes, scanner dependencies, support access, and disaster-recovery requirements for the installed release.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Client-server radiation-oncology software with DICOM image, RT Structure Set, and RT Dose exchange and export to treatment-planning systems; optional modules and scanner dependencies vary by release.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Training
Only trained and qualified radiation-therapy professionals should operate the software and review, correct, and approve its outputs. Local onboarding must include release-specific limitations, failure examples, escalation, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

VB50 expanded automatic contouring structures and converted head-and-neck contouring from atlas-based to deep-learning methods; its segmentation evaluation used 112 subjects. Procurement should map the installed build, modules, models, anatomies, inputs, and outputs to K201444 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that an earlier cleared release includes them.

Interoperability acceptance

Client-server radiation-oncology software with DICOM image, RT Structure Set, and RT Dose exchange and export to treatment-planning systems; optional modules and scanner dependencies vary by release.

exact submission · checked 2026-09-03

Test representative imports, exports, identifiers, orientation, geometry, structure names, units, failure handling, and round trips in the local environment.

Clinical acceptance

Use a signed local test set spanning supported anatomies, scanners, protocols, unusual or postsurgical anatomy, and small or complex structures. Measure edit burden, rejection, downstream plan effects, and reviewer agreement rather than relying only on average overlap metrics.

product family · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model total annual and per-plan cost against hands-on and elapsed time after review, correction, failed transfers, rework, support, upgrades, downtime, and any effect on plan quality or throughput.

product family · checked 2026-09-03

Vendor time-saving results are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.

product family · checked 2026-09-03

Trend failures and edits by exact software version, model, anatomy, scanner, protocol, and site.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K201444
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-08-13
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
26Fields reviewed
11Source classes checked
1Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 1 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, health technology guidance, reimbursement policy, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Limitations: Withdrawn - checked 2026-09-19 - Exact FDA submission

    Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared release was found. Obtain a written quote separating license basis, sites or users, enabled modules or models, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

10 sources - 2 history items

Source ledger

  1. FDA K201444: Syngo.via RT Image Suite

    U.S. Food and Drug Administration - Published 2020-08-13 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Artificial intelligence technologies to aid contouring for radiotherapy treatment planning

    National Institute for Health and Care Excellence - Published 2023-09-27 - Accessed 2026-09-02

    Scope: limitations, training, pricing, evidenceSummary, economics, monitoring, implementationCapabilities

  8. syngo.via RT Image Suite product page

    Siemens Healthineers - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, deployment, evidenceSummary, evidenceMetrics, currentCommercialContext, implementationCapabilities

  9. Clinical validation of Siemens syngo.via automatic contouring

    Advances in Radiation Oncology - Published 2023-01-16 - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, economics, monitoring, implementationCapabilities

  10. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K201444 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15
FDA-cleared K240398

RayStation 2023B, RayPlan 2023B, RayStation 2024A, RayPlan 2024A, RayStation 2024A SP3, RayPlan 2024A SP3

RaySearch Laboratories AB (PUBL)

Authorized purpose: RayStation and RayPlan releases covered by K240398 are configurable radiotherapy and medical-oncology software that proposes or supports treatment plans from user inputs, with authorized users required to review and approve plans before treatment.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-04-04
FDA-cleared K242822

ART-Plan+ (v.3.0.0)

Therapanacea SAS

Authorized purpose: ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-02-25
FDA-cleared K242994

OncoStudio (OS-01)

OncoSoft. Co., Ltd.

Authorized purpose: OncoStudio OS-01 creates initial deep-learning organs-at-risk contours from CT images of the head and neck, thorax, abdomen, and pelvis for radiation-oncology review, editing, and DICOM RT export.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-02-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history